label	id	title	authors	year	nonapproved	journal	corrauthorlocation	ctgnctid	statedgoal_safety	statedgoal_dosage	statedgoal_efficacy	statedgoal_pd	statedgoal_pk	statedgoal_other	sponsor_govt	sponsor_biotech	sponsor_pharma	sponsor_nonprofit	sponsor_ns	industry	preclinical citation in same indication	phase	phasestated	multicentre	shape	size	border	row	subindication	stage	conflictofinterest_disclosed	conflictofinterest	effectsize	randomisation	primary_outcome_blinding	allocation_blinding	description_of_withdrawals	study_design_dose_esc	study_design_dose_find	study_design_dose_rang	study_design_hist_cont	study_design_parallel	study_design_futility	study_design_simon2	study_design_placebo	study_design_crossover	study_design_invasv	study_design_is_other	study_design_other	no_comp_cites	duration_of_treatment (weeks)	duration_of_tx_imputed	concomitant_meds	paediatric_subjects	burdens_invasive_res_procedures	burdens_wash_out	burdens_other	burdens_washout_text	burdens_other_text	burdens_none	results_primary_endpoint	colour	results_toxicity	results_assessment_risk_benefit	stats_measure	clinicalinterest	Alpha	Beta	Min	Thres	date_of_pt_enrolment	date_of_closure	pub_date	query	bounce	sent may 1	response	address	total n	n receiving su evaluable for response	ORR n	G3-4	G3-5	Deaths	number of citations	novel citations	cited < 2 years	cited < 3 years18	2007	"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer"	"S. Faivre, C. Delbaldo, K. Vera, C. Robert, S. Lozahic, N. Lassau, C. Bello, S. Deprimo, N. Brega, G. Massimini, J.-P. Armand, P. Scigalla and E. Raymond"	2006	1	Journal of Clinical Oncology	France	n/a	0	0	NULL	NULL	0	NULL	NULL	NULL	1	NULL	NULL	1	1	Phase 1	Explicit	Single				P1	Advanced malignancies	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	0	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	None	42	Yes	No	None	NULL	NULL	NULL	NULL	NULL	0	Positive		Acceptable	Favourable	None	Yes					01.06.01	03.09.01	06.01.01						28	27	6	14	15	1	8	6	4	873	1793	"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma"	"R. J. Motzer, M. D. Michaelson, B. G. Redman, G. R. Hudes, G. Wilding, R. A. Figlin, M. S. Ginsberg, S. T. Kim, C. M. Baum, S. E. DePrimo, J. Z. Li, C. L. Bello, C. P. Theuer, D. J. George and B. I. Rini"	2006	1	Journal of Clinical Oncology	United States	n/a	1	NULL	1	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	0	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	RCC	n/a	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	None	39	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Positive	green	Acceptable	Favourable	95 CI	Yes	0.05	0.15		15%	03.01.01	03.07.01	06.01.01						63	63	25	7	7	0	6	4	0	644	1795	Activity of sunitinib in patients with advanced neuroendocrine tumors	"M. H. Kulke, H.-J. Lenz, N. J. Meropol, J. Posey, D. P. Ryan, J. Picus, E. Bergsland, K. Stuart, L. Tye, X. Huang, J. Z. Li, C. M. Baum and C. S. Fuchs"	2008	1	Journal of Clinical Oncology	United States	NCT00056693	1	NULL	1	NULL	NULL	NULL	NULL	NULL	1	1	NULL	1	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	NET	Advanced disease; not candidates for curative surgery	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	31	No	Unclear	None	NULL	NULL	NULL	NULL	NULL	0	Positive	green	Acceptable	Favourable	95 CI	Retest	0.05	0.15	5%	15%	03.03.01	05.11.01	08.07.10						109	107	11	26	27	1	12	5	8	87	2208	Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial	"G. D. Demetri, A. T. van Oosterom, C. R. Garrett, M. E. Blackstein, M. H. Shah, J. Verweij, G. McArthur, I. R. Judson, M. C. Heinrich, J. A. Morgan, J. Desai, C. D. Fletcher, S. George, C. L. Bello, X. Huang, C. M. Baum and P. G. Casali"	2006	1	Lancet	United States	NCT00075218	0	NULL	0	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	1	0	Phase 3	Explicit	Multi	circle	2 cm	thick	GIST	Imatinib resistant	Refractory	Disclosed	Conflict	n/a	Yes	Yes	Yes	Yes	NULL	NULL	NULL	NULL	1	NULL	NULL	1	1	NULL	NULL	NULL	None	10.4	No	No	None	NULL	0	NULL	NULL	NULL	1	Positive	green	Acceptable	Favourable	95 CI	Yes	0.05	0.1			03.12.01	05.01.01	06.10.10						312	207	57	2	2	0	6	2	1	651	1970	Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.[Erratum appears in J Clin Oncol. 2008 Jan 20;26(3):514]	"L. B. Saltz, L. S. Rosen, J. L. Marshall, R. J. Belt, H. I. Hurwitz, S. G. Eckhardt, E. K. Bergsland, D. G. Haller, A. C. Lockhart, C. M. Rocha Lima, X. Huang, S. E. DePrimo, E. Chow-Maneval, R. C. Chao and H. J. Lenz"	2007	1	Journal of Clinical Oncology	United States	n/a	0	NULL	0	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	1	1	Phase 2	Explicit	Multi	circle	1.5 cm	thick	Colorectal	metastatic	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	9.2	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Acceptable	Inconclusive	95 CI	Retest	0.05	0.15	5%	15%	03.12.01	05.11.01	07.10.20						82	82	1	12	12	0	16	8	0	663	338	A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease	"W. Fiedler, H. Serve, H. Dohner, M. Schwittay, O. G. Ottmann, A.-M. O'Farrell, C. L. Bello, R. Allred, W. C. Manning, J. M. Cherrington, S. G. Louie, W. Hong, N. M. Brega, G. Massimini, P. Scigalla, W. E. Berdel and D. K. Hossfeld"	2005	1	Blood	Germany	n/a	1	NULL	0	NULL	1	NULL	NULL	NULL	1	NULL	NULL	1	1	Phase 1	Explicit	Multi				AML	"refractory or resistant, not amenable to conventional therapies"	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	1	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	None	4	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Positive		Acceptable	Inconclusive	None	Retest					03.12.15	02.04.30	04.09.30	1		1	answered	fiedler@uke.uni-hamburg.de 	16	15	5	4	5	1	3	3	3	357	1692	Sunitinib in patients with metastatic renal cell carcinoma	"R. J. Motzer, B. I. Rini, R. M. Bukowski, B. D. Curti, D. J. George, G. R. Hudes, B. G. Redman, K. A. Margolin, J. R. Merchan, G. Wilding, M. S. Ginsberg, J. Bacik, S. T. Kim, C. M. Baum and M. D. Michaelson"	2006	1	JAMA	United States	NCT00077974	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	0	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	RCC	metastatic	Second line	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	single-arm	None	13	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Positive	green	Acceptable	Favourable	95 CI	Yes	0.1				04.02.01	04.11.01	06.07.07						106	106	36	16	17	1	7	7	3	717	1959	"Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane"	"H. J. Burstein, A. D. Elias, H. S. Rugo, M. A. Cobleigh, A. C. Wolff, P. D. Eisenberg, M. Lehman, B. J. Adams, C. L. Bello, S. E. DePrimo, C. M. Baum and K. D. Miller"	2008	1	Journal of Clinical Oncology	United States	NCT00078000	NULL	NULL	1	1	1	NULL	NULL	NULL	0	NULL	NULL	0	1	Phase 2	Explicit	Multi	circle	1.5 cm	thick	BC	Previously Treated With an Anthracycline and a Taxane	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	None	10	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Inconclusive	yellow	Acceptable	Favourable	95 CI	Yes	0.05	0.15	5%	10%	04.03.01	05.11.01	08.03.17						64	64	7	22	22	0	6	1	0	010	2450	Sunitinib versus interferon alfa in metastatic renal-cell carcinoma	"R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski, O. Rixe, S. Oudard, S. Negrier, C. Szczylik, S. T. Kim, I. Chen, P. W. Bycott, C. M. Baum and R. A. Figlin"	2007	0	New England Journal of Medicine	United States	NCT00098657	0	NULL	0	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	1	0	Phase 3	Explicit	Multi	circle	2 cm	thick	RCC	"Metastatic, clear-cell histologic"	Refractory	Disclosed	Conflict	4.7 to 6.2 months	Yes	Yes	Yes	Yes	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	24	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Positive	green	Acceptable	Favourable	95 CI	Yes	0.05	0.1			04.08.01	05.10.01	07.01.11						750	375	116			0	14	11	2	253	1813	Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma	"B. I. Rini, M. D. Michaelson, J. E. Rosenberg, R. M. Bukowski, J. A. Sosman, W. M. Stadler, T. E. Hutson, K. Margolin, C. S. Harmon, S. E. DePrimo, S. T. Kim, I. Chen and D. J. George"	2008	0	Journal of Clinical Oncology	United States	n/a	1	NULL	1	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	0	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	RCC	Bevacizumab-Refractory Metastatic Renal Cell Carcinoma	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	single arm	None	29	No	Unclear	None	NULL	NULL	NULL	NULL	NULL	0	Positive	green	Acceptable	Favourable	95 CI	Yes			5%	15%	04.12.01	08.03.01	08.08.01	1		1	answered	rinib2@ccf.org	61	61	14			1	1	1	1	18	1684	Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate	"K. Shirao, T. Nishida, T. Doi, Y. Komatsu, K. Muro, Y. Li, E. Ueda and A. Ohtsu"	2010	0	Investigational New Drugs	Japan	NCT00457743	0	0	0	0	0	NULL	NULL	NULL	0	NULL	NULL	0	0	Phase 1/2	Explicit	Multi	circle	1.5 cm	thick	GIST	Imatinib-resistant	Second line	Disclosed	Conflict	n/a	No	No	No	Yes	1	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	22	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Positive	green	Acceptable	Favourable	95 CI	Yes					05.01.01	08.08.01	09.09.03						36	36	4			0	6	0	0	067	1949	Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma	"B. Escudier, J. Roigas, S. Gillessen, U. Harmenberg, S. Srinivas, S. F. Mulder, G. Fountzilas, C. Peschel, P. Flodgren, E. C. Maneval, I. Chen and N. J. Vogelzang"	2009	0	Journal of Clinical Oncology	France	NCT00137423	0	NULL	0	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	0	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	RCC	Cytokine-Refractory	Refractory	Disclosed	Conflict	n/a	Yes	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	1	RCT	None	36	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Positive	green	Acceptable	Favourable	95 CI	Yes	0.05	0.1	5%	15%	05.07.01	06.02.01	09.08.03						107	107	21			0	9	2	2	511	2606	Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib	"K. A. Janeway, K. H. Albritton, A. D. Van Den Abbeele, G. Z. D'Amato, P. Pedrazzoli, S. Siena, J. Picus, J. E. Butrynski, M. Schlemmer, M. C. Heinrich and G. D. Demetri"	2009	0	Pediatric Blood & Cancer	United States	n/a	1	NULL	1	NULL	NULL	0	1	NULL	1	1	NULL	1	0	Phase 1	Not stated	Multi				GIST	Paediatric	Second line	Not disclosed	Unclear	n/a	No	No	No	No	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	Treatment-use	None	95	No	No	All	NULL	NULL	NULL	NULL	NULL	0	Positive		Acceptable	Favourable	None	Yes					05.09.15	06.01.15	09.03.26	1		1		gdemetri@partners.org 	7	7	1			0	8	3	1	362	214	"Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects"	"C. L. Bello, L. Sherman, J. Zhou, L. Verkh, J. Smeraglia, J. Mount and K. J. Klamerus"	2006	1	Anti-Cancer Drugs	United States	n/a	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	0	NULL	NULL	0	1	Phase 1	Explicit	Single				P1	n/a	First line	Disclosed	Conflict	80%-125% for 90% CI ratios	Yes	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	None	4	NULL	No	None	NULL	1	NULL	4 weeks	Fasting; dietary restrictions	0	Positive		Acceptable	Favourable	95 CI	Yes					05.10.15	06.01.01	06.03.01	1		1		carlo.bello@pfizer.com 	16	16	0	0	0	0	5	2	1	530	391	Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer	"S. Novello, G. V. Scagliotti, R. Rosell, M. A. Socinski, J. Brahmer, J. Atkins, C. Pallares, R. Burgess, L. Tye, P. Selaru, E. Wang, R. Chao and R. Govindan"	2009	1	British Journal of Cancer	Italy	n/a	0	NULL	0	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	0	1	Phase 2	Explicit	Multi	circle	1.5 cm	thick	NSCLC	n/a	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	NULL	NULL	None	18	Yes	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Acceptable	Favourable	95 CI	Yes	0.1	0.2	5%	15%	05.11.01	06.05.01	09.10.13						47	47	1	8	9	1	11	4	5	741	2533	Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib	"K. Zimmermann, A. Schmittel, U. Steiner, A. M. Asemissen, M. Knoedler, E. Thiel, K. Miller and U. Keilholz"	2009	0	Oncology	Germany	n/a	0	NULL	0	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	0	0	Phase 2	Not stated	Single	circle	1.5 cm	thick	RCC	Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib	Refractory	Not disclosed	Unclear	n/a	No	No	No	Yes	NULL	0	1	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	None	21.5	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Positive	green	Acceptable	Favourable	95 CI	Yes					05.11.01	06.07.01	09.03.24						80	22	4			0	4	1	2	458	1694	"A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety"	"H. Uemura, N. Shinohara, T. Yuasa, Y. Tomita, H. Fujimoto, M. Niwakawa, S. Mugiya, T. Miki, N. Nonomura, M. Takahashi, Y. Hasegawa, N. Agata, B. Houk, S. Naito and H. Akaza"	2010	0	Japanese Journal of Clinical Oncology	Japan	NCT00254540	0	NULL	0	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	0	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	RCC	n/a	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	single-arm	None	24	Yes	No	None	NULL	NULL	NULL	NULL	NULL	0	Positive	green	Acceptable	Favourable	95 CI	Yes	0.025	0.2			05.12.15	07.02.01	09.11.07	1	bounce	0		akazah@md.tsukuba.ac.jp 	51	51	24			0	4	2	1	224	1685	Phase II study of sunitinib as second-line treatment for advanced gastric cancer	"Y.-J. Bang, Y.-K. Kang, W. K. Kang, N. Boku, H. C. Chung, J.-S. Chen, T. Doi, Y. Sun, L. Shen, S. Qin, W.-T. Ng, J. M. Tursi, M. J. Lechuga, D. R. Lu, A. Ruiz-Garcia and A. Sobrero"	2011	1	Investigational New Drugs	Korea South	NCT00226811	1	NULL	1	1	1	1	NULL	NULL	0	NULL	NULL	0	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	Gastric	Refractory to chemotherapy for advanced disease or not amenable to therapy with curative intent	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	6.9	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Acceptable	Favourable	95 CI	Retest	0.05	0.15	5%	15%	06.01.15	08.05.15	10.05.12	1		1		bangyj@snu.ac.kr 	78	78	2	27	31	4	5	0	0	021	2216	"Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study"	"S. Faivre, E. Raymond, E. Boucher, J. Douillard, H. Y. Lim, J. S. Kim, M. Zappa, S. Lanzalone, X. Lin, S. Deprimo, C. Harmon, A. Ruiz-Garcia, M. J. Lechuga and A. L. Cheng"	2009	1	Lancet Oncology	France	NCT00247676	1	NULL	1	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	0	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	HCC	n/a	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	12	Yes	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Unacceptable	Unfavourable	95 CI	No	0.05	0.15	5%	15%	06.02.01	06.07.01	09.07.07						37	37	1	5	9	4	6	0	1	459	2185	Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma	"A. A. Thomas, B. I. Rini, B. R. Lane, J. Garcia, R. Dreicer, E. A. Klein, A. C. Novick and S. C. Campbell"	2009	0	Journal of Urology	United States	n/a	1	NULL	1	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	0	0	Phase 1	Not stated	Single				RCC	mostly unresectable or large burden of extrarenal disease 	Refractory	Not disclosed	Unclear	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	"One arm, set dose design"	None	12	Yes	No	None	NULL	NULL	NULL	NULL	NULL	0	Positive		Acceptable	Favourable	None	Retest					06.02.01	07.01.01	08.12.18						19	19	2			0	4	4	2	212	370	Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer	"H. Wildiers, C. Fontaine, P. Vuylsteke, M. Martens, J. L. Canon, W. Wynendaele, C. Focan, J. De Greve, P. Squifflet and R. Paridaens"	2010	1	Breast Cancer Research & Treatment	Belgium	n/a	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	0	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	BC	HER2-negative	Refractory	Disclosed	No conflict	n/a	Yes	No	No	Yes	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	NULL	NULL	None	21.7	No	No	None	NULL	NULL	NULL	NULL	NULL	1	Negative	red	Unacceptable	Unfavourable	None	No					06.02.01	09.03.01	10.07.22						55	55	0	36	36	0	1	0	1	129	147	Phase II study of sunitinib in men with advanced prostate cancer	"M. Dror Michaelson, M. M. Regan, W. K. Oh, D. S. Kaufman, K. Olivier, S. Z. Michaelson, B. Spicer, C. Gurski, P. W. Kantoff and M. R. Smith"	2009	1	Annals of Oncology	United States	n/a	0	NULL	0	NULL	NULL	NULL	1	NULL	NULL	1	NULL	0	0	Phase 2	Explicit	Single	circle	1.5 cm	thick	PC	castration-resistant	Refractory	Not disclosed	Unclear	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	12	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Acceptable	Inconclusive	None	Retest	0.05	0.1	5%	25%	06.03.01	06.12.01	09.05.01						36	36	0	6	6	0	0	0	0	045	1862	"Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study"	"A. X. Zhu, D. V. Sahani, D. G. Duda, E. Di Tomaso, M. Ancukiewicz, O. A. Catalano, V. Sindhwani, L. S. Blaszkowsky, S. S. Yoon, J. Lahdenranta, P. Bhargava, J. Meyerhardt, J. W. Clark, E. L. Kwak, A. F. Hezel, R. Miksad, T. A. Abrams, P. C. Enzinger, C. S. Fuchs, D. P. Ryan and R. K. Jain"	2009	1	Journal of Clinical Oncology	United States	N/A	1	NULL	1	NULL	NULL	NULL	1	NULL	1	NULL	NULL	1	0	Phase 2	Explicit	Single	circle	1.5 cm	thick	HCC	Advanced disease	Refractory	Disclosed	Conflict	69%	No	Yes	No	No	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	None	16.9	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Acceptable	Favourable	95 CI	Retest		0.1			06.04.01	07.11.01	09.05.26						34	34	1	6	6	0	3	0	2	372	1703	Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey	"I. Yildiz, F. Sen, M. Basaran, M. Ekenel, F. Agaoglu, E. Darendeliler, H. M. Tunc, F. Ozcan and S. Bavbek"	2011	0	Japanese Journal of Clinical Oncology	Turkey	n/a	0	NULL	0	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	0	0	Phase 2	Not stated	Single	circle	1.5 cm	thick	RCC	n/a	Refractory	Disclosed	No conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	consectutive cohort	None	40	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Positive	green	Acceptable	Favourable	95 CI	Yes	0.05				06.04.01	10.08.01	11.10.19						74	74	20			0	7	0	2	22	481	A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer	"G. Fountzilas, A. Fragkoulidi, A. Kalogera-Fountzila, M. Nikolaidou, M. Bobos, J. Calderaro, F. Andreiuolo and M. Marselos"	2010	1	Cancer Chemotherapy & Pharmacology	Greece	n/a	1	NULL	1	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	0	0	Phase 2	Explicit	Single	circle	1.5 cm	thick	HNC	n/a	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	12	Yes	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Acceptable	Unfavourable	95 CI	No	0.05	0.8	20%	35%	06.05.15	10.01.01	09.08.05	1		1		fountzil@auth.gr 	17	17	0	7	7	0	2	1	0	168	151	Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease	"E. Jonasch, I. E. McCutcheon, S. G. Waguespack, S. Wen, D. W. Davis, L. A. Smith, N. M. Tannir, D. S. Gombos, G. N. Fuller and S. F. Matin"	2011	1	Annals of Oncology	United States	n/a	0	NULL	0	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	0	0	Phase 2	Explicit	Single	circle	1.5 cm	thick	VHL	nonmetastatic	First line	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	0	0	NULL	NULL	NULL	NULL	NULL	NULL	1	Single arm	None	19.2	Yes	No	None	NULL	NULL	NULL	NULL	NULL	0	Positive	green	Acceptable	Inconclusive	None	Unclear	0.1	0.17	5%	30%	06.06.01	09.06.01	11.12.01						15	15	6	5	5	0	2	1	1	146	1909	"Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer"	"M. A. Socinski, S. Novello, J. R. Brahmer, R. Rosell, J. M. Sanchez, C. P. Belani, R. Govindan, J. N. Atkins, H. H. Gillenwater, C. Pallares, L. Tye, P. Selaru, R. C. Chao and G. V. Scagliotti"	2008	1	Journal of Clinical Oncology	United States	n/a	1	NULL	1	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	0	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	NSCLC	Stage IIIB or IV NSCLC after failure of at least one platinum-based chemotherapy regimen	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	11	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Positive	green	Acceptable	Favourable	95 CI	Yes	0.1	0.1	5%	10%	06.06.15	08.01.01	08.02.01	1	bounce	0		socinski@med.unc.edu	64	63	7	18	22	4	8	4	5	560	145	Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity	"J. Bellmunt, J. L. Gonzalez-Larriba, C. Prior, P. Maroto, J. Carles, D. Castellano, B. Mellado, E. Gallardo, J. L. Perez-Gracia, G. Aguilar, X. Villanueva, J. Albanell and A. Calvo"	2011	1	Annals of Oncology	Spain	NCT01118039	NULL	NULL	1	1	NULL	NULL	0	NULL	0	NULL	NULL	0	1	Phase 2	Explicit	Multi	circle	1.5 cm	thick	Urothelial	Urothelial cancer patients ineligible to receive cisplatin- based chemotherapy	First line	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	20.8	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Acceptable	Inconclusive	95 CI	Retest	0.05	0.1	10%	10%	06.07.01	09.09.01	11.03.21						38	38	3	4	6	2	11	8	3	350	1686	Phase II study of sunitinib malate in head and neck squamous cell carcinoma	"N. W. Choong, M. Kozloff, D. Taber, H. S. Hu, J. Wade, 3rd, P. Ivy, T. G. Karrison, A. Dekker, E. E. Vokes and E. E. W. Cohen"	2010	1	Investigational New Drugs	United States	n/a	0	NULL	0	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	0	0	Phase 2	Explicit	Single	circle	1.5 cm	thick	HNC	metastatic and/or recurrent	Refractory	Not disclosed	Unclear	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	12	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Acceptable	Unfavourable	None	No	0.1	0.1	10%	30%	06.08.01	09.03.01	09.08.04						22	22	1	4	4	0	6	2	0	123	1643	"Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma"	"S. Tariq Mahmood, S. Agresta, C. E. Vigil, X. Zhao, G. Han, G. D'Amato, C. E. Calitri, M. Dean, C. Garrett, M. J. Schell, S. Antonia and A. Chiappori"	2011	1	International Journal of Cancer	United States	NCT00400569	0	NULL	0	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	0	0	Phase 2	Explicit	Single	circle	1.5 cm	thick	Soft tissue sarcoma	"Metastatic liposarcoma, leiomyosarcoma and malignant fibrous histiocytoma"	Refractory	Disclosed	Conflict	n/a	No	No	No	No	NULL	0	0	NULL	NULL	NULL	1	NULL	NULL	NULL	0	NULL	None	8	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Acceptable	Inconclusive	95 CI	Retest	0.1	0.14	5%	15%	06.09.01	07.08.01	11.03.25						48	47	0	5	5	0	1	0	0	069	1952	Phase II study of sunitinib in patients with metastatic urothelial cancer	"D. J. Gallagher, M. I. Milowsky, S. R. Gerst, N. Ishill, J. Riches, A. Regazzi, M. G. Boyle, A. Trout, A.-M. Flaherty and D. F. Bajorin"	2010	1	Journal of Clinical Oncology	United States	n/a	0	NULL	0	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	0	1	Phase 2	Explicit	Single	circle	1.5 cm	thick	Urothelial	n/a	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	9.4	Yes	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Unacceptable	Unfavourable	p-value	Retest	0.05	0.1	5%	20%	06.09.01	09.01.01	10.02.08						77	77	4	7	8	1	11	6	4	743	2906	Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma	"Barrios CH, Hernandez-Barajas D, Brown MP et al"	2009	0	"34th congress of the European Society for Medical Oncology, Berlin, Germany, September 20Ð24 (Poster presenta- tion; Abstract P-7122)"	Brazil	NCT00338884	1	NULL	1	NULL	1	1	NULL	NULL	0	NULL	NULL	0	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	RCC	"Metastases, treatment-naive, clear cell histology"	First line	Disclosed	Conflict	37%	No	No	No	Yes	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	None	45	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Positive	green	Acceptable	Favourable	95 CI	Yes				37%	06.09.01	09.06.01	11.09.06						120	119	42			2	5	0	2	270	777	Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis	"E. Apostolidou, H. Kantarjian, D. Thomas, I. Burger, G. Borthakur and S. Verstovsek"	2010	1	"Clinical lymphoma, myeloma & leukemia"	United States	n/a	1	NULL	1	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	0	0	Phase 2	Explicit	Single	circle	1.5 cm	thick	Myelofibrosis	n/a	Refractory	Disclosed	No conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	1	Gehan 2-stage design	None	22.5	No	No	None	1	NULL	NULL	NULL	NULL	0	Negative	red	Unacceptable	Unfavourable	None	No	0.5	0.5	5%	20%	06.10.01	07.03.01	10.08.01						14	14	0	3	3	0	2	0	0	015	1558	Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study	"M. L. Hensley, M. W. Sill, D. R. Scribner, Jr., J. Brown, R. L. Debernardo, E. M. Hartenbach, C. K. McCourt, J. R. Bosscher and P. A. Gehrig"	2009	1	Gynecologic Oncology	United States	n/a	0	NULL	0	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	0	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	Uterine leiomyosarcoma	recurrent or persistant	Refractory	Disclosed	No conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	26	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Unacceptable	Unfavourable	95 CI	No	0.084	0.11	10%	30%	06.10.02	07.05.21	09.10.06	1		1	answered	hensleym@mskcc.org 	25	25	2	7	8	1	18	18	2	213	719	Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study	"S. G. Dubois, S. Shusterman, A. M. Ingle, C. H. Ahern, J. M. Reid, B. Wu, S. Baruchel, J. Glade-Bender, P. Ivy, H. E. Grier, P. C. Adamson and S. M. Blaney"	2011	1	Clinical Cancer Research	United States	NCT00387920	NULL	1	1	1	1	NULL	1	NULL	1	1	NULL	1	1	Phase 1	Explicit	Multi				P1	pediatric	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	0	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	None	6	Yes	No	All	NULL	NULL	NULL	NULL	NULL	0	Positive		Unacceptable	Inconclusive	None	Retest					06.10.16	11.03.18	11.06.20	1		1	answered	duboiss@peds.ucsf.edu 	23	23	0	33	33	0	15	7	5	7	2457	A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603)	"E. M. O'Reilly, D. Niedzwiecki, M. Hall, D. Hollis, T. Bekaii-Saab, T. Pluard, K. Douglas, G. K. Abou-Alfa, H. L. Kindler, R. L. Schilsky, R. M. Goldberg, Cancer and B. Leukemia Group"	2010	1	Oncologist	United States	NCT00397787 	NULL	NULL	1	NULL	NULL	NULL	1	NULL	1	NULL	NULL	1	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	Pancreatic	Metastatic Pancreatic Adenocarcinoma 	Second line	Not disclosed	Unclear	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	Three stage	None	6	Yes	Unclear	None	NULL	NULL	NULL	NULL	NULL	0	Positive	green	Unacceptable	Unfavourable	None	No	n/a	n/a	n/a	10%	06.11.01	07.11.01	10.12.10						77	74	1	14	16	2				6	1155	"An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer"	"M. Moehler, A. Mueller, J. T. Hartmann, M. P. Ebert, S. E. Al-Batran, P. Reimer, M. Weihrauch, F. Lordick, T. Trarbach, S. Biesterfeld, M. Kabisch, D. Wachtlin, P. R. Galle and O. German Arbeitsgemeinschaft Internistische"	2011	1	European Journal of Cancer	Germany	NCT00411151	NULL	NULL	1	NULL	NULL	1	1	NULL	NULL	NULL	NULL	0	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	Gastric	adenocarcinoma	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	None	4	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Acceptable	Unfavourable	95 CI	Yes	0.05	0.104	5%	20%	06.12.01	11.01.01	11.05.09	1		1		moehler@mail.uni-mainz.de 	52	52	2	19	19	0	5	0	0	028	64	A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study	"J. J. Biagi, A. M. Oza, H. I. Chalchal, R. Grimshaw, S. L. Ellard, U. Lee, H. Hirte, J. Sederias, S. P. Ivy and E. A. Eisenhauer"	2011	1	Annals of Oncology	Canada	n/a	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	0	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	OC	n/a	Refractory	Disclosed	No conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	18	Yes	Unclear	None	NULL	NULL	NULL	NULL	NULL	0	Inconclusive	yellow	Acceptable	Inconclusive		Retest	0.12	0.11	5%	20%	07.01.01	08.04.01	10.08.12						31	31	1	5	5	0	10	0	0	234	1553	A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184	"H. J. Mackay, A. Tinker, E. Winquist, G. Thomas, K. Swenerton, A. Oza, J. Sederias, P. Ivy and E. A. Eisenhauer"	2010	1	Gynecologic Oncology	Canada	n/a	NULL	NULL	0	NULL	NULL	NULL	1	NULL	NULL	1	NULL	0	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	Cervical	"locally advanced squamous/adenosquamous/adenocarcinoma of the cervix, up to one therapy before, life expectancy <12, no antiagiogenic agents used and more!"	Refractory	Disclosed	No conflict	20%	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	None	12	Yes	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Unacceptable	Unfavourable	95 CI	No	0.07	0.1	5%	20%	07.01.01	08.05.01	09.09.08						19	19	0	8	8	0	3	0	1	119	2056	Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma	"R. J. Motzer, T. E. Hutson, M. R. Olsen, G. R. Hudes, J. M. Burke, W. J. Edenfield, G. Wilding, N. Agarwal, J. A. Thompson, D. Cella, A. Bello, B. Korytowsky, J. Yuan, O. Valota, B. Martell, S. Hariharan and R. A. Figlin"	2012	0	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	United States	NCT00267748	1	NULL	1	NULL	NULL	1	NULL	NULL	0	NULL	NULL	0	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	RCC	n/a	First line	Disclosed	Conflict	n/a	Yes	No	No	Yes	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	NULL	NULL	None	42.9	No	Unclear	None	NULL	NULL	NULL	NULL	NULL	0	Positive	green	Acceptable	Favourable	95 CI	Yes					07.01.01	08.06.01	12.03.19						292	292	88			3	3	1	1	338	2601	Phase II study of sunitinib malate following hepatic artery embolization for metastatic neuroendocrine tumors	"J. Strosberg, A. Cheema, T. Campos, T. Valone, L. Kvols and H. L. Moffitt"	2011	1	Pancreas	United States	n/a	1	NULL	1	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	1	0	Phase 2	Explicit	Single	circle	1.5 cm	thick	NET	"metastatic, hepatic artery embolization"	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	None	52	No	No	None	NULL	NULL	1	NULL	Hepatic arterial embolization	0	Positive	green	Acceptable	Favourable	95 CI	Yes	0.1	0.1			07.01.01	10.04.01	12.02.08						39	39	28	6	6	0	3	1	0	164	349	Sunitinib in relapsed or refractory diffuse large B cell lymphoma: Results of a phase II multi-center study of the ncic clinical trials group	"R. Buckstein, J. Kuruvilla, N. Chua, C. Lee, A. D. Macdonald, A. J. Al-Tourah, A. Foo, W. Walsh, S. P. Ivy, M. Crump and E. Eisenhauer"	2009	1	Blood	Canada	n/a	1	NULL	1	1	NULL	NULL	NULL	NULL	NULL	1	NULL	0	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	Lymphoma	"diffuse large B-cell lymphoma, relapsed or refractory"	Refractory	Disclosed	No conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	NULL	8	NULL	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	NULL	Unfavourable	95 CI	No	0.12	0.11	5%	20%	07.02.01	08.09.01	11.04.04						17	19	0	3	3	0	14	10	5	65	65	A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: Current progress and challenges in evaluating molecularly targeted agents in ACC	"N. G. Chau, S. J. Hotte, E. X. Chen, S. F. Chin, S. Turner, L. Wang and L. L. Siu"	2012	1	Annals of Oncology	Canada	NCT00886132	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	1	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	Adenoid cystic carcinoma	n/a	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	26	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Acceptable	Unfavourable	None	Retest			5%	20%	07.02.01	08.12.01	11.11.11						14	14	0	5	5	0	8	7	1	23	154	Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study	"K. Oechsle, F. Honecker, T. Cheng, F. Mayer, P. Czaykowski, E. Winquist, L. Wood, M. Fenner, S. Glaesener, J. T. Hartmann, K. Chi, C. Bokemeyer and C. Kollmannsberger"	2011	1	Annals of Oncology	Canada	NCT00371553	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	0	1	Phase 2	Explicit	Multi	circle	1.5 cm	thick	Germ cell	cisplatin-refractory	Refractory	Disclosed	No conflict	n/a	No	No	No	No	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	6	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Acceptable	Inconclusive	95 CI	Retest	0.05	0.2	5%	20%	07.02.01	10.01.01	11.03.17						32	33	0	2	2	0	6	6	1	131	1956	Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01	"J.-P. H. Machiels, S. Henry, S. Zanetta, M.-C. Kaminsky, N. Michoux, D. Rommel, S. Schmitz, E. Bompas, A.-F. Dillies, S. Faivre, A. Moxhon, T. Duprez and J. Guigay"	2010	1	Journal of Clinical Oncology	Belgium	n/a	0	NULL	0	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	0	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	HNC	Palliative 	Refractory	Disclosed	Conflict	25%	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	7	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Unacceptable	Unfavourable	95 CI	Retest	0.15	0.1	10%	25%	07.03.01	08.08.01	09.11.16						38	38	1	12	12	0	3	1	0	135	1687	Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma	"A. M. Molina, D. R. Feldman, M. S. Ginsberg, G. Kroog, S. K. Tickoo, X. Jia, M. Georges, S. Patil, M. S. Baum, V. E. Reuter and R. J. Motzer"	2012	0	Investigational New Drugs	United States	n/a	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	0	0	Phase 2	Explicit	Single	circle	1.5 cm	thick	RCC	"metastatic, mainly papillary RCC"	Refractory	Not disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	23.8	Yes	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Acceptable	Unfavourable	95 CI	No	0.05	0.2	5%	20%	07.03.01	09.10.01	12.02.01						23	23	1			0	11	7	0	126	1907	Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas	"S. George, P. Merriam, R. G. Maki, A. D. Van den Abbeele, J. T. Yap, T. Akhurst, D. C. Harmon, G. Bhuchar, M. M. O'Mara, D. R. D'Adamo, J. Morgan, G. K. Schwartz, A. J. Wagner, J. E. Butrynski, G. D. Demetri and M. L. Keohan"	2009	1	Journal of Clinical Oncology	United States	 NCT00474994	NULL	NULL	0	NULL	NULL	NULL	1	NULL	1	1	NULL	1	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	Soft tissue sarcoma	Fewer than 3 prior cytotoxic therapies	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	None	24	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Acceptable	Inconclusive	None	Retest	0.05	0.1	5%	20%	07.04.01	08.03.01	09.05.18						53	53	0	5	5	0	4	1	3	427	2142	Brief report: A phase II study of sunitinib in malignant pleural mesothelioma. the NCIC clinical trials group	"S. A. Laurie, A. Gupta, Q. Chu, C. W. Lee, W. Morzycki, R. Feld, A. H. Foo, J. Seely, J. R. Goffin, F. Laberge, N. Murray, S. Rao, G. Nicholas, J. Laskin, T. Reiman, D. Sauciuc and L. Seymour"	2011	1	Journal of Thoracic Oncology	Canada	n/a	0	NULL	0	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	0	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	Malignant pleural mesothelioma	Cohort 1: <=3 prior lines of cytotoxic chemotherapy; Cohort 2: chemotherapy-naive 	Second line	Disclosed	No conflict	n/a	No	No	No	No	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	18	Yes	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Acceptable	Unfavourable	None	No	0.1	0.1	10%	30%	07.04.01	09.06.01	11.11.01						35	35	0	6	6	0	0	0	0	054	480	"A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period"	"C. D. Britten, F. Kabbinavar, J. R. Hecht, C. L. Bello, J. Li, C. Baum and D. Slamon"	2008	1	Cancer Chemotherapy & Pharmacology	United States	n/a	1	NULL	0	NULL	1	1	1	NULL	1	NULL	NULL	1	1	Phase 1	Explicit	Single				P1	n/a	Refractory	Not disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL		None	9	Yes	Unclear	None	NULL	NULL	NULL	NULL	NULL	0	Positive		Acceptable	Favourable	None	Yes					07.04.15	08.01.01	07.05.16	1	bounce	0		cbritten@mednet.ucla.edu 	12	12	1	3	3	0	13	6	5	64	2100	Phase II study of sunitinib malate in patients with recurrent high-grade glioma	"B. Neyns, J. Sadones, C. Chaskis, M. Dujardin, H. Everaert, S. Lv, J. Duerinck, O. Tynninen, N. Nupponen, A. Michotte and J. De Greve"	2011	1	Journal of Neuro-Oncology	Belgium	n/a	NULL	NULL	0	NULL	NULL	NULL	0	NULL	1	1	NULL	1	1	Phase 2	Explicit	Single	circle	1.5 cm	thick	Glioma	High-grade	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	4.8	No	No	None	NULL	1	NULL	14 days	NULL	0	Negative	red	Unacceptable	Unfavourable		No	0.1	0.1	5%	20%	07.06.01	08.03.01	10.09.25						21	21	0	4	4	0	4	1	0	132	2449	Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.[Erratum appears in N Engl J Med. 2011 Mar 17;364(11):1082]	"E. Raymond, L. Dahan, J.-L. Raoul, Y.-J. Bang, I. Borbath, C. Lombard-Bohas, J. Valle, P. Metrakos, D. Smith, A. Vinik, J.-S. Chen, D. Horsch, P. Hammel, B. Wiedenmann, E. Van Cutsem, S. Patyna, D. R. Lu, C. Blanckmeister, R. Chao and P. Ruszniewski"	2011	1	New England Journal of Medicine	France	NCT00428597	0	NULL	0	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	0	1	Phase 3	Explicit	Multi	circle	2 cm	thick	NET	well-differentiated	NULL	Disclosed	Conflict	n/a	Yes	Yes	Yes	Yes	NULL	NULL	NULL	NULL	1	NULL	NULL	1	NULL	NULL	NULL	NULL	None	18.2	Yes	Yes	None	NULL	NULL	NULL	NULL	NULL	0	Positive	green	Acceptable	Favourable	95 CI	Yes	0.05	0.1			07.06.01	09.04.01	11.02.10						171	86	8	12	13	1	7	4	0	242	2825	A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ	"A. Bex, C. Blank, W. Meinhardt, H. van Tinteren, S. Horenblas and J. Haanen"	2011	0	Urology	Netherlands	n/a	0	NULL	0	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	0	0	Phase 2	Explicit	Single	circle	1.5 cm	thick	RCC	"Metastatic Clear-cell Renal Carcinoma, Primary tumour in situ"	Refractory	Disclosed	Conflict	n/a	No	No	No	No	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	12	Yes	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Acceptable	Inconclusive	None	Retest	0.05	0.2	10%	25%	07.06.01	10.11.02	11.07.29	1		1	answered	a.bex@nki.nl 	22	22	7			0	5	1	2	352	2164	Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer	"B. J. Schneider, S. M. Gadgeel, N. Ramnath, A. J. Wozniak, G. K. Dy, S. Daignault and G. P. Kalemkerian"	2011	1	Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer	United States	n/a	0	NULL	0	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	0	0	Phase 2	Explicit	Single	circle	1.5 cm	thick	SCLC	Extensive-Stage	Second line	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	17.3	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Unacceptable	Unfavourable	95 CI	No	0.05	0.2			07.07.01	09.01.01	11.06.01						16	16	0	4	4	0	0	0	0	014	720	"Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation"	"L. L. Carr, D. A. Mankoff, B. H. Goulart, K. D. Eaton, P. T. Capell, E. M. Kell, J. E. Bauman and R. G. Martins"	2010	1	Clinical Cancer Research	United States	n/a	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	1	0	Phase 2	Explicit	Single	circle	1.5 cm	thick	Thyroid	n/a	Refractory	Not disclosed	Conflict	n/a	No	No	No	Yes	NULL	1	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	None	1	No	Unclear	None	NULL	NULL	NULL	NULL	NULL	0	Inconclusive	yellow	Acceptable	Favourable	95 CI	Yes	0.05	0.08	10%	33%	07.08.01	09.02.01	10.09.16						35	35	11	12	13	1	4	3	2	322	2468	Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06)	"D. Koeberle, M. Montemurro, P. Samaras, P. Majno, M. Simcock, A. Limacher, S. Lerch, K. Kovacs, R. Inauen, V. Hess, P. Saletti, M. Borner, A. Roth and G. Bodoky"	2010	1	Oncologist	Switzerland	NCT00699374	NULL	NULL	0	NULL	NULL	NULL	1	NULL	1	NULL	0	1	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	HCC	n/a	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	12	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Positive	green	Acceptable	Favourable	95 CI	Yes	0.05	0.1			07.09.01	08.08.01	10.03.04						45	45	1	12	12	0	8	6	5	548	2182	Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma	"N. J. Hellenthal, W. Underwood, R. Penetrante, A. Litwin, S. Zhang, G. E. Wilding, B. T. Teh and H. L. Kim"	2010	0	Journal of Urology	United States	n/a	0	NULL	0	NULL	NULL	NULL	0	NULL	0	NULL	NULL	0	0	Phase 2	Not stated	Single	circle	1.5 cm	thick	RCC	Candidate for nephrectomy	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	None	13	Yes	No	None	NULL	NULL	NULL	NULL	NULL	0	Positive	green	Acceptable	Favourable	None	Yes	0.05				07.09.01	09.04.01	10.09.01						20	20	1			0	4	2	2	237	2218	"Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial"	"S. Negrier, G. Gravis, D. Perol, C. Chevreau, R. Delva, J.-O. Bay, E. Blanc, C. Ferlay, L. Geoffrois, F. Rolland, E. Legouffe, E. Sevin, B. Laguerre and B. Escudier"	2011	0	Lancet Oncology	France	NCT00619268	NULL	NULL	0	NULL	NULL	NULL	1	NULL	1	NULL	NULL	1	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	RCC	untreated metastatic RCC	Refractory	Disclosed	Conflict	n/a	Yes	Yes	Yes	Yes	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	Fleming's single stage	None	35.5	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Unacceptable	Unfavourable	95 CI	No					08.03.01	09.05.01	11.06.10						171	42	12			0	6	6	3	425	1955	Phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer (SCLC)	"J. Han, K. Y. Lim, H. Y. Kim, J. H. Han, S. H. Oh, T. Yun, H. T. Kim and J. S. Lee"	2011	1	Journal of Clinical Oncology	Korea South	NCT00620347	0	NULL	0	NULL	NULL	NULL	1	NULL	1	NULL	NULL	1	1	Phase 2	Explicit	Single	circle	1.5 cm	thick	SCLC	Relapsed or refractory	Refractory	Disclosed	No conflict	n/a	No	Yes	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	None	6.8	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Unacceptable	Unfavourable	95 CI	Retest	0.05	0.1	15%	35%	08.03.01	10.10.01	12.11.20						25	25	2	15	15	0	4	0	0	261	175	Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy	"G. Sonpavde, P. O. Periman, D. Bernold, D. Weckstein, M. T. Fleming, M. D. Galsky, W. R. Berry, F. Zhan, K. A. Boehm, L. Asmar and T. E. Hutson"	2010	1	Annals of Oncology	United States	NCT00599313?	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	0	1	Phase 2	Explicit	Multi	circle	1.5 cm	thick	PC	Castration-resistant prostate cancer following docetaxel-based chemotherapy	Refractory	Not disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	None	19.4	No	No	None	NULL	NULL	NULL	NULL	NULL	0	Positive	green	Unacceptable	Inconclusive	None	Retest	0.05	0.2			08.05.15	10.01.01	09.07.24	1	bounce	0		Guru.Sonpavde@USOncology.com	36	36	2	6	8	2	12	9	3	555	1554	"A phase II trial of sunitinib in recurrent and refractory ovarian, fallopian tube, and peritoneal carcinoma"	"S. Campos, R. Penson, S. Berlin, U. Matulonis and N. Horowitz"	2010	1	Gynecologic Oncology	United States	NCT00768144	0	NULL	0	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	0	0	Phase 2	Explicit	Single	circle	1.5 cm	thick	OC	n/a	Refractory	Disclosed	Conflict	n/a	No	No	No	Yes	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	None	16	Yes	No	None	NULL	NULL	NULL	NULL	NULL	0	Inconclusive	yellow	Unacceptable	Inconclusive	95 CI	Retest	0.05	0.15	5%	20%	08.09.15	08.09.22	12.08.09	1	out-of-office reply	1	answered	scampos@partners.org 	35	36	3	33	33	0	6	1	4	420	2059	Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function	"R. Khosravan, M. Toh, M. Garrett, J. La Fargue, G. Ni, T. C. Marbury, S. K. Swan, N. M. Lunde and C. L. Bello"	2010	1	Journal of Clinical Pharmacology	United States	n/a	0	NULL	NULL	NULL	0	NULL	NULL	NULL	0	NULL	NULL	0	1	Phase 1	Explicit	Multi				P1	n/a	First line	Disclosed	Conflict	n/a	No	No	No	No	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	NULL	NULL	None	1	No	NULL	None	NULL	NULL	NULL	NULL	NULL	1	Positive		NULL	NULL		NULL					09.04.15	10.01.01	09.09.24	1		1		Reza.Khosravan@pfizer.com	24	24	0	2	2	0	19	14	6	1233	1153	"A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study"	"J. H. Yi, S. Thongprasert, J. Lee, D. C. Doval, S. H. Park, J. O. Park, Y. S. Park, W. K. Kang and H. Y. Lim"	2012	1	European Journal of Cancer	Korea South	NCT01082809	1	NULL	1	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	1	0	Phase 2	Explicit	Multi	circle	1.5 cm	thick	Biliary tract carcinoma	"Second-line, Advanced Stage"	Refractory	Disclosed	No conflict	n/a	No	No	No	Yes	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	None	7.4	No	No	None	NULL	NULL	1	NULL	CT scans (not really burdensome)	0	Negative	red	Acceptable	Favourable	95 CI	Yes	0.05	0.1			09.05.01	10.10.01	11.12.14						56	56	5	12	12	0	7	2	1	316	1688	Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors	"D. R. Feldman, S. Turkula, M. S. Ginsberg, N. Ishill, S. Patil, M. Carousso, G. J. Bosl and R. J. Motzer"	2010	1	Investigational New Drugs	United States	n/a	NULL	NULL	0	NULL	NULL	NULL	0	NULL	1	NULL	NULL	1	0	Phase 2	Explicit	Single	circle	1.5 cm	thick	Germ cell	n/a	Refractory	Not disclosed	Conflict	n/a	No	No	No	No	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	NULL	NULL	NULL	NULL	None	6	Yes	No	None	NULL	NULL	NULL	NULL	NULL	0	Negative	red	Acceptable	Inconclusive	None	No	0.05	0.2	5%	20%	09.05.15	10.01.01	09.06.23	1	out-of-office reply	0		feldmand@mskcc.org	10	10	0	6	6	0	1	0	0	0																																																																																				33				